| Literature DB >> 28677030 |
Yifen Shen1, Li Zhang1, Donglin Wang2, Yifeng Bao1, Chao Liu3, Zhiwei Xu4, Wei Huang1, Chun Cheng5.
Abstract
Dual-specificity tyrosine-regulated kinase 2 (DYRK2), a protein kinase that phosphorylates its substrates on serine/threonine, is expressed in numerous human tumors, but little is known about its role in the pathophysiology of glioma. In this study, we made an effort to explore the expression and function in human glioma. Western blot and immunohistochemistry analysis were performed to investigate the expression of DYRK2 protein in glioma tissues in 84 patients. Wound healing and transwell assay were carried out to determine the cell migration ability. We showed that the level of DYRK2 was significantly decreased in high-grade glioma tissues compared with low-grade tissues. In addition, the expression level of DYRK2 was positively correlated with glioma pathological grade and E-cadherin expression. Kaplane-Meier analysis revealed that low expression of DYRK2 was related to poor prognosis of glioma patients. Furthermore, wound healing and transwell assay revealed that DYRK2 could suppress cell migration and affect the expression levels of E-cadherin and vimentin through PI3K/AKT/GSK3β signaling pathway. Taken together, our results implied that DYRK2 could serve as a promising prognostic biomarker as well as a potential therapeutical target of glioma.Entities:
Keywords: DYRK2; E-cadherin; Glioma; Migration
Mesh：
Substances：
Year: 2017 PMID： 28677030 DOI： 10.1007/s11064-017-2345-2
Source DB: PubMed Journal: Neurochem Res ISSN： 0364-3190 Impact factor: 3.996